AIM: @entity1643 is the leading cause of disability and a major health problem around the world. As of today, symptomatic relief is the best option offered to @entity1 , with mixed results. This study will review the use of mesenchymal stem cell (MSC) technology in the conservative and surgical treatments of @entity179 ( @entity179 ). METHODS: A series of PubMed-National Library of Medicine searches were performed. Only articles in English journals or with published with English language translations were included. Level of evidence of the selected articles was assessed. RESULTS: There are multiple in-vitro and animal studies describing successful intervertebral disc (IVD) repair/regeneration with the use of live MSC therapy. Only 3 @entity1 studies (22 @entity1 ) with inconsistent results have been performed using bone marrow MSCs injected into diseased IVDs in @entity1 with @entity179 . There exist multiple in-vitro and animal studies describing successful bony fusion with the use of MSC-containing bone graft substitutes. Only 3 retrospective @entity1 studies (115 @entity1 ) using CBM in spinal fusion have been performed with successful fusion rates ranging from 90.2%-92.3%. However, these studies lacked power and had significant conflicts of interest. There are multiple challenges with the use of MSC technology in @entity1 . CONCLUSION: MSCs may be a promising therapy in the treatment of @entity179 . However, their lack of success in @entity1 models leaves room for further research and focus in this field. Currently, there is no clinical evidence to support the use of this technology in the conservative or surgical management of @entity1 with @entity179 .

Mesenchymal stem cell technology in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'human'] @entity1643 :: ('MESH:D017116', 'Disease') :: ['Low back pain'] @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative disc disease', 'DDD']
@entity179 :: (MESH:D019636,Disease) :: ['degenerative disc disease']
